Even though I believe I’m a pretty good planner and can strategize with the best of ‘em, last week threw me into a planning frenzy. I was anticipating my first in-person ALS clinic visit after nearly a year of online appointments with my neurologist. Pre-pandemic, I had many in-person…

A first patient has been dosed in a Phase 2 clinical trial testing Alector’s investigational antibody AL001 as a treatment for amyotrophic lateral sclerosis (ALS) associated with C9orf72 mutations. The trial is expected to enroll an estimated 45 ALS patients, who will be randomly assigned to AL001 or a placebo,…

A technology based on artificial intelligence is helping to spot biomarkers and document the progression of amyotrophic lateral sclerosis (ALS) in a large speech study being conducted by EverythingALS. The technology, developed by Modality.ai, is a web-based computer program that uses audio (speech) and video (facial) recordings…

ProMIS Neurosciences is advancing the development of antibodies against toxic TDP-43 protein clumps for the treatment of amyotrophic lateral sclerosis (ALS), the company announced. Through lab and animal tests, ProMIS said in a press release, the company plans to validate its current antibodies, which include extracellular antibodies delivered…

“But if I had the Chance to start all over I would be wishing today On a four-leaf clover … If I could turn back The hands of time.” The 45 rpm single “Turn Back the Hands of Time” by rhythm and blues artist Tyrone Davis was a…

Health Canada has agreed to review Amylyx Pharmaceuticals‘ application seeking approval of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). “We are pleased that our submission has been accepted for review by Health Canada, and we are committed to serving those affected by ALS in the…

Last week, I had several email exchanges with ALS patients who wrote about their feelings of anger because ALS had robbed them of the life they had planned to live. I certainly can relate. I felt exactly the same way after my diagnosis. I told them what had helped…

Bringing artificial intelligence (AI) to the development of small molecule therapies for amyotrophic lateral sclerosis (ALS) and other neurological diseases is the goal of a business partnership in Asia. The newly signed agreement is between Insilico Medicine, an AI-driven drug discovery company based in Hong Kong, and 4B Technologies of Suzhou,…

Dropping the levels of microRNA-218 (miR-218) — a small molecule that regulates the activity of other genes — below a certain threshold leads to severe motor neuron damage, paralysis, and death in a mouse model of amyotrophic lateral sclerosis (ALS), a study shows. The findings, combined with the fact that…

A national agency in Norway has given AB Science the go-ahead to resume enrollment in AB19001, a Phase 3 clinical trial investigating the safety and efficacy of the company’s investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS). AB had voluntarily suspended recruitment and treatment…